Patients Use Cases

A pragmatic risk stratification approach with LIVERFASt™

Clinical Information

  • Presents to PCP with moderate fatigue and malaise
  • Patient gained 20 pounds over the last 12 months
  • Uncontrolled Diabetic
  • Currently taking Diovan HCT 320mg/25mg and Janumet 50/500mg
  • Past medical history of hypertension, diabetes, and
  • CKD stage 3
  • No family history of medical problems
  • BMI 36
  • BP 160/90

Steps

  1. Clinician orders LIVERFASt™ for the patient
  2. LIVERFASt Proprietary CPT Code 0166U
  3. The patient has a simple fasting blood test of the 10 biomarkers
  4. The lab provides results of the 10 biomarker results
  5. The 10 biomarker results are input into Fibronostics web portal
  6. Fibronostics’ AI technology generates LIVERFASt™ results immediately

Laboratory Results

  • Fasting Blood Glucose: 260 mg/dl
  • Triglycerides: 165 mg/dl
  • HDL: 50 mg/dl
  • LDL: 140 mg/dl
  • AST: 65 IU/L
  • ALT: 70 IU/L

Clinical Assessment

  • Poorly controlled Diabetes Mellitus
  • Morbid Obesity
  • Hypertension
  • Elevated Liver Function Tests

What to do next?

  • Risk management of Diabetes Mellitus
  • Hypertension management

Order LIVERFASt™

“There should be a high index of suspicion for NAFLD and NASH in patients with type 2 diabetes” (Chalassani N et al. Hepatology 2018. AASLD CPG)
“In patients with type 2 diabetes, the presence of NAFLD should be looked for irrespective of liver enzyme levels, since type 2 diabetes patients are at high risk of disease progression “ (Chalassani N et al. Hepatology 2018. AASLD CPG)

Fibrosis

  • 0.61
  • F3
  • Significant Fibrosis

Activity

  • 0.66
  • A3
  • Marked Activity

Steatosis

  • 0.80
  • S3
  • Marked Steatosis


Patient stratified as high risk of NASH or advanced fibrosis.

“Patients with steatosis identified by steatosis biomarkers and having metabolic medium/high risk (indicative of significant fibrosis or cirrhosis using fibrosis biomarkers), in the presence or not of abnormal liver enzymes should be referred to a specialist for in-depth assessment of disease severity, decision to perform liver biopsy, initiate monitoring/therapy.” (EASL-EASD-EASO. J Hepatol 2016 CPG)

Clinical Information

  • Presents to PCP with moderate fatigue and malaise
  • Patient gained 20 pounds over the last 12 months
  • Uncontrolled Diabetic
  • Currently taking Diovan HCT 320mg/25mg and Janumet 50/500mg
  • Past medical history of hypertension, diabetes, and
  • CKD stage 3
  • No family history of medical problems
  • BMI 36
  • BP 160/90

Steps

  1. Clinician orders LIVERFASt™ for the patient
  2. LIVERFASt Proprietary CPT Code 0166U
  3. The patient has a simple fasting blood test of the 10 biomarkers
  4. The lab provides results of the 10 biomarker results
  5. The 10 biomarker results are input into Fibronostics web portal
  6. Fibronostics’ AI technology generates LIVERFASt™ results immediately

Laboratory Results

  • Fasting Blood Glucose: 260 mg/dl
  • Triglycerides: 165 mg/dl
  • HDL: 50 mg/dl
  • LDL: 140 mg/dl
  • AST: 65 IU/L
  • ALT: 70 IU/L

Clinical Assessment

  • Poorly controlled Diabetes Mellitus
  • Morbid Obesity
  • Hypertension
  • Elevated Liver Function Tests

What to do next?

  • Risk management of Diabetes Mellitus
  • Hypertension management

Order LIVERFASt™

“There should be a high index of suspicion for NAFLD and NASH in patients with type 2 diabetes” (Chalassani N et al. Hepatology 2018. AASLD CPG)
“In patients with type 2 diabetes, the presence of NAFLD should be looked for irrespective of liver enzyme levels, since type 2 diabetes patients are at high risk of disease progression “ (Chalassani N et al. Hepatology 2018. AASLD CPG)

Fibrosis

  • 0.61
  • F3
  • Significant Fibrosis

Activity

  • 0.66
  • A3
  • Marked Activity

Steatosis

  • 0.80
  • S3
  • Marked Steatosis


Patient stratified as high risk of NASH or advanced fibrosis.

“Patients with steatosis identified by steatosis biomarkers and having metabolic medium/high risk (indicative of significant fibrosis or cirrhosis using fibrosis biomarkers), in the presence or not of abnormal liver enzymes should be referred to a specialist for in-depth assessment of disease severity, decision to perform liver biopsy, initiate monitoring/therapy.” (EASL-EASD-EASO. J Hepatol 2016 CPG)

Clinical Information

  • Presents to PCP with moderate fatigue and malaise
  • Patient gained 20 pounds over the last 12 months
  • Uncontrolled Diabetic
  • Currently taking Diovan HCT 320mg/25mg and Janumet 50/500mg
  • Past medical history of hypertension, diabetes, and
  • CKD stage 3
  • No family history of medical problems
  • BMI 36
  • BP 160/90

Steps

  1. Clinician orders LIVERFASt™ for the patient
  2. LIVERFASt Proprietary CPT Code 0166U
  3. The patient has a simple fasting blood test of the 10 biomarkers
  4. The lab provides results of the 10 biomarker results
  5. The 10 biomarker results are input into Fibronostics web portal
  6. Fibronostics’ AI technology generates LIVERFASt™ results immediately

Laboratory Results

  • Fasting Blood Glucose: 260 mg/dl
  • Triglycerides: 165 mg/dl
  • HDL: 50 mg/dl
  • LDL: 140 mg/dl
  • AST: 65 IU/L
  • ALT: 70 IU/L

Clinical Assessment

  • Poorly controlled Diabetes Mellitus
  • Morbid Obesity
  • Hypertension
  • Elevated Liver Function Tests

What to do next?

  • Risk management of Diabetes Mellitus
  • Hypertension management

Order LIVERFASt™

“There should be a high index of suspicion for NAFLD and NASH in patients with type 2 diabetes” (Chalassani N et al. Hepatology 2018. AASLD CPG)
“In patients with type 2 diabetes, the presence of NAFLD should be looked for irrespective of liver enzyme levels, since type 2 diabetes patients are at high risk of disease progression “ (Chalassani N et al. Hepatology 2018. AASLD CPG)

Fibrosis

  • 0.61
  • F3
  • Significant Fibrosis

Activity

  • 0.66
  • A3
  • Marked Activity

Steatosis

  • 0.80
  • S3
  • Marked Steatosis


Patient stratified as high risk of NASH or advanced fibrosis.

“Patients with steatosis identified by steatosis biomarkers and having metabolic medium/high risk (indicative of significant fibrosis or cirrhosis using fibrosis biomarkers), in the presence or not of abnormal liver enzymes should be referred to a specialist for in-depth assessment of disease severity, decision to perform liver biopsy, initiate monitoring/therapy.” (EASL-EASD-EASO. J Hepatol 2016 CPG)